These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 30593436)

  • 1. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
    Martin J; Cheng Q; Laurent SA; Thaler FS; Beenken AE; Meinl E; Krönke G; Hiepe F; Alexander T
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39409173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
    Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
    Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus.
    Benitez A; Torralba K; Ngo M; Salto LM; Choi KS; De Vera ME; Payne KJ
    Lupus; 2019 Oct; 28(11):1337-1343. PubMed ID: 31423896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
    Jacobi AM; Huang W; Wang T; Freimuth W; Sanz I; Furie R; Mackay M; Aranow C; Diamond B; Davidson A
    Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
    Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
    Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I; Axelsson M; Gunnarsson I
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
    Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
    Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab therapy in systemic lupus erythematosus.
    Zouali M; Uy EA
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.
    Scholz JL; Oropallo MA; Sindhava V; Goenka R; Cancro MP
    Lupus; 2013 Apr; 22(4):350-60. PubMed ID: 23553778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.